7/11/2013

Data presented at the ADA 73rd Scientific Sessions revealed hospitalized type 2 diabetes patients who either took once-daily oral sitagliptin, sitagliptin plus glargine or basal bolus attained similar improvements in glycemic control. Researchers found no differences in complication rates or length of stay between the groups.

Related Summaries